The below text is from a press release from ImmusanT.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2®, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients’ tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet. There are currently no approved medicines available for people with celiac disease, who must manage their condition by eliminating gluten-containing foods from their diet.
Advancing the earlier Nexvax2 clinical trial, the new program underway in Australia and New Zealand is a randomized, double-blind, placebo-controlled Phase 1b study evaluating multiple ascending doses of Nexvax2 for the induction of gluten tolerance in patients on a gluten-free diet. ImmusanT expects to enroll 84 subjects at approximately four study sites in the two countries in order to evaluate safety, tolerability and pharmacokinetics, and to select doses for investigation in subsequent studies.
The second study, a randomized, double-blind, placebo-controlled Phase 1 trial being conducted in the U.S. is to determine the safety, tolerability and pharmacokinetic profile of Nexvax2 in patients with celiac disease well controlled by a gluten-free diet. ImmusanT plans to enroll 30 adult subjects at approximately four trial sites.
In ImmusanT’s international trials, patients will have a confirmed diagnosis of celiac disease and carry the immune recognition gene HLA-DQ2. Up to 90 percent of individuals with celiac disease have this gene. Furthermore, prospective patients will be screened using the company’s companion diagnostic technology to identify suitable candidates for the therapeutic vaccine. ImmusanT will use this novel blood test to measure gluten-reactive T cells in celiac disease as a potential marker for immune modulation with Nexvax2.
Read more in the press release from ImmusanT.